Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Tarceva Prescribers for Non-Small Cell Lung Cancer (US)(?)

Council Members in this Study Group: 48

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.Donald Fleming, MD
Division Head of Hematology and Oncology
Davis Health System, Inc.

Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed journals and remains involved in clinical...

Ben Ebrahimi, MD
Consultant
Medical Consulting Firm of Dr. Ben Ebrahimi

Ben Ebrahimi, MD, is Director of Clinical Trials at Wilshire Oncology Medical Group. Dr. Ebrahimi oversees clinical trials in various tumor types and treats a variety of cancer patients including lung, breast, colorectal, and lymphomas. These clinical trials include biological agents as well as targeted...

Haitham Al-Okk, MD, Assistant Clinical Professor - Hematology-Oncology, Mahr Cancer CenterHaitham Al-Okk, MD
Assistant Clinical Professor - Hematology-Oncology
Mahr Cancer Center

Haitham Al-Okk, MD, is a Specialist in Hematology-Oncology at Graves-Gilbert Cancer Clinic, a multi-specialty medical group in Kentucky. Dr. Al-Okk is board certified in Internal Medicine and Medical Oncology, and fellowship trained in Hematology-Oncology. He specializes in lung, breast, and colorectal...

Chandra Belani, MD
Professor & Deputy Director of Cancer Institute
THE PENNSYLVANIA STATE UNIVERSITY

Chandra Belani, MD, is a Distinguished Professor of Medicine in the Division of Hematology-Oncology at the Penn State College of Medicine. He is also a Deputy Director of the Penn State Cancer Institute. Dr. Belani's major research interest is lung cancer, including drug development, chemoprevention,...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Bcl-2 apoptosis inhibition: The next "best" thing? | 08-29-2008
Author: GLG Expert Contributor

Bcl-2 inhibition by small molecules stands to be the next avenue for antineoplastic therapy- Looks like the real deal!

So Much for GVAX.... for now? | 08-29-2008
Author: GLG Expert Contributor

No reason for the increased mortality vs Chemo alone was identified. Cell Genesys is looking into where to go now.

Velcade in myeloma 1st line. Am I s?urprised | 08-29-2008
Author: GLG Expert Contributor

Velcade + classic Melphalan/ Prednisone  (MP) is better than MP alone. No surprise

Amgen's long awaited product to treat chronic ITP will be well receive. | 08-25-2008
Analysis of: Amgen Blood-Disorder Drug Gains Clearance | online.wsj.com
Author: GLG Expert Contributor

Chronic ITP is not all that uncommon and becomes a quality of life issue with chronic steroid use as well as agents that are normaly used in neoplasia and even derivatives of male hormones.

Artificial red blood cells (RBC'S): preliminary but very promising. | 08-21-2008
Analysis of: Scientists Find Way to Create Red Blood Cells | online.wsj.com
Author: GLG Expert Contributor

Advanced Cell Technology in Worcester, Mass., the University of Illinois at Chicago and the Mayo Clinic in Rochester, Minn. scientists say they've found an efficient way to make red blood cells from human embryonic stem cells. Impreesive!

View All GLG News by members of this Study Group

Most Common Company Types:

  • Office Based Private Practice or Clinic
  • Academic Medical Center/Hospital or Clinic
  • Non-Academic Community Hospital or Clinic
  • Government/Military Hospital or Clinic

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Director
  • Owner
  • Medical Director
  • Consultant

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-08-30T01:45:15.453